- Original research
- Open Access
Engineering anti-Lewis-Y hu3S193 antibodies with improved therapeutic ratio for radioimmunotherapy of epithelial cancers
© Burvenich et al. 2016
- Received: 26 January 2016
- Accepted: 3 March 2016
- Published: 17 March 2016
The aim of the study was to explore Fc mutations of a humanised anti-Lewis-Y antibody (IgG1) hu3S193 as a strategy to improve therapeutic ratios for therapeutic payload delivery.
Four hu3S193 variants (I253A, H310A, H435A and I253A/H310A) were generated via site-directed mutagenesis and radiolabelled with diagnostic isotopes iodine-125 or indium-111. Biodistribution studies in Lewis-Y-positive tumour-bearing mice were used to calculate the dose in tumours and organs for therapeutic isotopes (iodine-131, yttrium-90 and lutetium-177).
111In-labelled I253A and H435A showed similar slow kinetics (t 1/2β, 63.2 and 62.2 h, respectively) and a maximum tumour uptake of 33.11 ± 4.05 and 33.69 ± 3.77 percentage injected dose per gramme (%ID/g), respectively. 111In-labelled I253A/H310A cleared fastest (t 1/2β, 9.1 h) with the lowest maximum tumour uptake (23.72 ± 0.85 %ID/g). The highest increase in tumour-to-blood area under the curve (AUC) ratio was observed with the metal-labelled mutants (90Y and 177Lu). 177Lu-CHX-A" DTPA-hu3S193 I253A/H310A (6:1) showed the highest tumour-to-blood AUC ratio compared to wild type (3:1) and other variants and doubling of calculated dose to tumour based on red marrow dose constraints.
These results suggest that hu3S193 Fc can be engineered with improved therapeutic ratios for 90Y- and 177Lu-based therapy, with the best candidate being hu3S193 I253A/H310A for 177Lu-based therapy.
- Therapeutic ratio
- Payload delivery
- Antibody engineering
- Small animal imaging
The use of monoclonal antibodies (mAbs) to deliver radioisotopes to tumour sites (radioimmunotherapy (RIT)) has been very successful in the treatment of haematologic tumours as the targeted radiation is able to kill the highly radiosensitive leukemias and lymphomas. Treatment of solid tumours that are generally more radioresistant has been less successful due to several factors including long serum persistence, poor tumour penetration and slow diffusion rates of mAbs . The large molecular size of mAbs (150 kDa) does not allow renal excretion. In addition, the Fc fragment of IgG antibodies interacts with the neonatal Fc receptor (FcRn, Brambell receptor), preventing it from being degraded in the lysosomes [2–6]. The resulting long serum persistence of large-sized mAbs cause dose-limiting radiotoxicity to normal tissues, principally red marrow.
The choice of the optimal radionuclide for RIT depends on its intended use. Physical properties such as path length, emission energy and physical half-life must correlate with a particular tumour size. 131I (E max, 0.66 MeV), suitable for tumours <1 cm, and 90Y (E max, 2.3 MeV), suitable for tumours >1 cm, are both β-particle-emitting isotopes and have been used in >95 % of clinical RIT trials . Similar to 131I, 177Lu (E max, 0.5 MeV) has been identified as having favourable characteristics for treatment of tumours particularly with heterogeneous antigen expression . Whilst 90Y and 177Lu labels are retained intracellularly after endocytosis, the 131I label is rapidly released from the cells [8, 9].
Early engineering approaches to reduce the serum half-life of antibodies and improve therapeutic ratios were based on reduction in antibody size by deletion of constant domains [1, 10, 11]. Our laboratory has previously evaluated smaller forms such as diabody, F(ab′)2 and tetrameric scFv constructs without an Fc fragment. These constructs showed a rapid elimination phase compared to wild-type IgG1, more rapid tumour targeting with the maximum tumour uptake observed at an earlier time point but strongly reduced maximal tumour uptake [12–14]. Another approach studied in preclinical studies to improve therapeutic ratio is pretargeted RIT. The multistep targeting approach allows the antibody to clear first before administrating the therapeutic radionuclide, and this approach has shown high increases in therapeutic ratio [1, 15].
The FcRn receptor recycles IgG antibodies into the blood circulation. During the last decade, the Fc-FcRn binding site has been well characterised, with I253, H310 in the CH2 domain and H435 in the CH3 domain identified as the key residues involved in the Fc-FcRn binding [16–19]. The FcRn-mediated IgG recycling can be described as a three-step process: (1) passive pinocytosis of IgG into endothelial cells; (2) in the acidic environment of endosomes (pH <6.5), histidine residues in the Fc fragment of IgG become protonated and this allows high-affinity binding of IgG to FcRn; and (3) unbound IgG will undergo lysosomal degradation whilst FcRn-bound IgG is released back into the blood circulation . Therefore, more recent engineering approaches to reduce the serum half-life of antibodies or Fc-coupled biological compounds used for payload delivery focus on mutating the specific amino acids in the CH2 or CH3 domain of the Fc fragment involved in the binding site of FcRn. Recycling of the variants is reduced, due to their diminished interaction with the FcRn receptor at pH <6.5. Most work has been done with radiolabelled Fc-containing antibody fragments such as scFv-Fc [20–23] and a minibody . Only one intact radiolabelled antibody (chTNT-3) carrying the I253A mutation has been studied in biodistribution studies and imaging studies .
We recently produced anti-Lewis-Y (Ley) humanised IgG1 variants carrying specific mutations in the Fc-FcRn binding region and investigated their binding properties to murine FcRn (muFcRn) and human FcRn (huFcRn) in vitro and in vivo . A good correlation was found with low in vitro binding to FcRn corresponding to fast blood clearance rates. Differences in blood clearance rates were observed between the murine and human FcRn mouse model, showing that one alanine mutation in the Fc-huFcRn binding site (i.e. I253A, H310A or H435A) was sufficient to completely abrogate binding to huFcRn and generate hu3S193 antibodies with clearance rates as fast as hu3S193 antibody fragments (e.g. (Fab′)2) without an Fc fragment. In contrast, two alanine mutations in hu3S193 Fc (e.g. I253A/H310A) were necessary to completely abrogate binding to muFcRn. Single non-alanine variants of hu3S193 that were able to completely abrogate muFcRn binding were I253D, I253P, H310D and H310E .
This study explored the impact of amino acid substitutions on conserved residues of hu3S193 that have been shown to be critical for maintaining serum persistence of human IgG1 antibodies as a means to improve therapeutic ratios for RIT in solid tumours using intact antibodies. Hu3S193 has been shown to have significant anti-tumour effect in animal models for delivery of radioisotopes, including 131I, 90Y and 177Lu [26–29]. A first-in-man phase I trial of hu3S193 in patients with Ley expressing tumours clearly showed the potential for delivery of radioisotopes using hu3S193 for selective targeting of solid tumours . The utility of hu3S193 mutants in cancer diagnosis and therapy were evaluated by pharmacokinetic, biodistribution, dosimetry and immunoscintigraphy studies in tumour-bearing mice.
Construction of hu3S193 mutant antibodies
The construction and production of hu3S193 and huA33 has been described before [31, 32]. The hu3S193 heavy chain (HC) was ligated into the pEE6.4 mammalian expression vector (Lonza Biologics, Slough, UK) via a HindIII and EcoRI double digest (pEE6.4/hu3S193 HC). pEE6.4/hu3S193 HC was used as a template for site-directed mutagenesis (GeneTailor™ Site-Directed Mutagenesis System (Invitrogen) or QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene) to introduce the following substitutions in the CH2 and CH3 domains: I253A, H310A, H435A and I253A/H310A . The hu3S193 kappa light chain was ligated into the pEE14.4 mammalian expression vector containing the glutamine synthetase gene (Lonza Biologics) via a HindIII and EcoRI double digest. For the simultaneous expression of each mutated hu3S193 antibody, light and mutated heavy chain genes were cloned into a double-gene vector (pDGV) using a NotI and PvuI double digest. Freestyle 293-F cells (1 × 106 cells/mL) were transfected with the pDGV constructs according to the manufacturer’s instructions (Invitrogen). Supernatants were harvested at 96 h post transfection. Hu3S193 antibodies were purified using HiTrap KappaSelect columns (GE Healthcare). Purified proteins were analysed by SDS-PAGE under non-reducing conditions and evaluated by size exclusion chromatography on a Superdex 200 HR 10/30 column (GE Healthcare) using 0.01 mol/L sodium phosphate and 0.15 mol/L NaCl (pH 7.2) as elution buffer.
In vitro binding to Lewis-Y and protein A of hu3S193 mutant antibodies
The Lewis-Y binding activity of hu3S193 antibodies was determined by BIAcore analysis using a synthetic Lewis-Y tetrasaccharide coupled to BSA (Alberta Research Council, Edmonton, Alberta, Canada) on a CM5 chip using a BIAcore 2000 as described (BIAcore AB, Uppsala, Sweden) . Hu3S193 antibody samples were diluted in HBS buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3.4 mM di-Na-EDTA and 0.005 % Tween 20). Aliquots (60 μL) were injected over the sensor chip surface at a flow rate of 30 μL/min. After the injection phase, dissociation was monitored by flowing HBS over the chip surface for 300 s. Bound antibody was eluted, and the chip surface was regenerated between samples by injection of 100 mM HCl. For kinetic analysis, varying concentrations of hu3S193 wild type and mutants were injected (10, 19, 38, 75 and 150 nmol/L). Global analysis using a 1:1 Langmuir model fit was performed using BIA-evaluation version 4.1.1 software.
Fluorescence-activated cell sorter (FACS) analysis was done on Lewis-Y-positive A431 skin cancer cells. Aliquots of 2 × 105 cells were incubated with hu3S193 antibodies (200 nmol/L) in DMEM/F12 medium containing 10 % foetal bovine serum on ice. After washing the cells with PBS, cells were incubated with a goat phycoerythrin-conjugated anti-human IgG (Sigma) and incubated on ice for 30 min. Cells were washed with phosphate-buffered saline and resuspended in a final volume of 300 μL. In control samples, primary antibody was omitted. Flow cytometric analysis was done using a Guava EasyCyte Plus flow cytometer. Cancer cell populations were gated based on forward and side scatter variables. Data analysis was done using WinMDI (Joseph Trotter).
Radiolabelling of hu3S193 antibodies
Hu3S193 antibodies were radiolabelled with four isotopes: 125I, 131I, 111In and 177Lu. Iodine-125 and lutetium-177 were obtained from PerkinElmer (PerkinElmer Life and Analytical Sciences, Waltham, MA), iodine-131 was obtained from ANSTO (ANSTO, Menai, Australia) and indium-111 was obtained from MDS Nordion (Canada).
Radioiodination was performed using pH-neutralised isotopes, catalysed by iodogen-coated glass beads as previously published [12, 33]. After a 10-min incubation period, the reaction mixture was purified through a Sephadex G50 desalting column (Sigma-Aldrich, Sydney, Australia) equilibrated with 0.9 % NaCl containing 0.05 % human serum albumin.
Radiolabelling of the hu3S193 antibody constructs with indium-111 and lutetium-177 was done by using the bifunctional metal ion chelate C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid (CHX-A″ DTPA) [34, 35]. A chelate to antibody ratio of 3:1 was employed, using 0.1 M sodium bicarbonate buffer (pH 8.6) containing 0.9 % NaCl. Incubation was allowed for 16 h at room temperature. Under these conditions, one to two chelates are expected per antibody molecule. The radiolabelled mixture was purified through a Sephadex G50 desalting column equilibrated with 0.9 % NaCl containing 0.05 % human serum albumin.
Radiolabelling was performed on the day of injection into mice. Prior to injection, the percentage of unbound radionuclide content was determined by ITLC as previously described . Determination of the immunoreactivity of radiolabelled hu3S193 antibody constructs was performed by a single-point binding assay, where 10 × 106 Ley-positive A431 cells were incubated with 20 ng of radiolabelled antibody constructs for 45 min at room temperature with continuous mixing throughout to keep the cells in suspension. Cells were washed three times, and pellets were measured in a gamma counter (Cobra II, Model 5002, Packard Instruments, Canberra, Australia). Three samples of radiolabelled antibody at the same concentration as that initially added to the cells were measured at the same time of the cell pellets, and immunoreactivity was calculated: (cpm cell pellet/mean cpm radioactive antibody standards) × 100. Serum stability was analysed by determination of immunoreactivity on the day of injection, at 48 h, and 7 days after 20 ng of radiolabelled antibody was incubated in human serum at 37 °C.
Blood clearance studies
Female athymic mice (BALB/c nu/nu; 4–6 weeks; Animal Resources Centre) were injected in the tail vein with 0.185 MBq 125I-mutant (2.5–5 μg, 5 μCi) and 0.185 MBq 131I-hu3S193 (2.5–5 μg, 5 μCi) wild type antibody (n = 5). A separate group of athymic mice were injected with 0.185 MBq 125I- hu3S193 mutant (2.5–5 μg, 5 μCi) and 0.185 MBq 111In-hu3S193 (2.5–5 μg, 5 μCi) mutant (n = 5). All animal studies were approved by the Austin Hospital Animal Ethics Committee and were conducted in compliance with NHMRC Australian code of practice for the care and use of animals for scientific purposes. Blood samples (10–20 μL) were collected from groups of five at 5 min, 1, 2, 4, 8, 24, 48, 72, 120, 168, 240 and 336 h after injection of radioactive antibodies. Samples were counted in a gamma counter (Cobra II). Standards prepared from injected material were counted each time with blood samples enabling calculations to be corrected for physical decay of isotope.
Biodistribution studies were done with athymic non-tumour-bearing mice (BALB/c nu/nu, female, 4–6 weeks) or mice bearing A431 tumours (111In, 0.657 ± 0.216 g; 131I, 0.515 ± 0.195 g; 177Lu, 0.466 ± 0.086 g). To study the tumour uptake and biodistribution in normal tissues of radioiodinated hu3S193 variants, A431 tumour-bearing BALB/c nu/nu mice were co-injected intravenously with 0.185–0.74 MBq (5–20 μCi) 131I-hu3S193 variants (2–6 μg protein) and 0.185–0.74 MBq 125I-hu3S193 wild type (2–6 μg protein). In a second study, 0.185–0.74 MBq 111In-CHX-A″ DTPA-labelled mutant (2–6 μg protein) and 0.185-0.74 MBq 125I-labelled hu3S193 wild type (2–6 μg protein) were co-injected. 111In-CHX-A″ DTPA-labelled wild type and 125I-hu3S193 wild type were also injected as a control group. 125I-hu3S193 wild type was used as an internal control in all injected animals to enable direct comparison between the different mutants. Typically, groups of four to five mice were sacrificed at 4, 24, 48, 72, 120, 168, and 240 or 288 h after injection of radiolabelled antibodies. For evaluation of 177Lu-labelled antibodies, mice were sacrificed at 48 h after injection. At the designated time points, groups of mice (n = 4–5) were humanely sacrificed by over-inhalation of isoflurane. Mice were bled by cardiac puncture, and tumours and organs (skin, liver, spleen, small intestine, stomach, kidney, brain, bone (femur), lungs and heart) were immediately removed and blotted dry. All samples were weighed and counted in a dual gamma scintillation counter (Cobra II, Packard Instruments). Triplicate standards prepared from the injected material were counted at each time point with tissue and tumour samples enabling calculations to be corrected for the physical decay of the isotopes. Results of the radiolabelled antibody distribution over time were calculated as the mean percentage injected dose per gramme (%ID/g ± SD) for each mutant and parental hu3S193 per time point.
Pharmacokinetic analysis and predictive dosimetry
Antibody serum concentrations were expressed as percentage injected dose per millilitre (%ID/mL), and the blood concentrations (μg/mL) were calculated. A two-compartment IV bolus model with macro-parameters, no lag time and first order elimination (WinNonlin Model 8) was fitted to serum data obtained from blood clearance studies for each animal using unweighted non-linear, least squares with WinNonLin version 5.2 (Pharsight Corp., Mountain View, CA). Estimates were determined for the pharmacokinetic parameters: alpha half-life (t 1/2α), beta half-life (t 1/2β), area under the curve extrapolated to infinity (AUC0-∞) and mean residence time (MRT). Alpha half-lives of mutant hu3S193 were constrained to be smaller or equal to the alpha half-life of hu3S193 wild type. Significant differences in these values were examined by comparing the coefficient of variation (CV %) for the estimated parameters.
To estimate radioimmunotherapeutic applications for 90Y- or 177Lu-labelled mutants, biodistribution data obtained with 111In-CHX-A″ DTPA-labelled antibodies were used to generate time-activity curves for the calculations of predictive radiation doses for the bone marrow, liver, kidneys and tumour. Identical biodistribution and biologic clearance of 111In-, 90Y- and 177Lu-labelled antibodies were assumed. Predictive dosimetric analysis was also done for 131I-labelled antibodies based on biodistribution data obtained with 125I-labelled antibodies. As radiation absorbed doses are proportional to %ID/g, time-activity curves for the blood, liver, kidneys and tumour were integrated over time to calculate area under the curve (AUC). Time-activity curves generated from biodistribution data were corrected for radiodecay. Therefore, the pharmacokinetic values calculated from such data refer to pharmacological values of the antibodies in the absence of radioisotope. Appropriate physical half-life corrections were applied to convert %IDpharmacological/g to %IDradioisotope/g, and the time-activity curves were fit to either a two or three exponential function from which the AUC is determined for 90Y, 177Lu and 131I. AUC integration from zero to infinity was done by the sum of a trapezoidal integration of the measurement range (AUC0–288 h) plus an extrapolated model fit for the extrapolated range (AUC288 h–∞). To calculate accumulated activity, photon dose and edge effects were ignored. Dose to red marrow was determined from blood concentrations using a baseline value of 0.1 .
Nano-SPECT and MR imaging
All the SPECT and MR scans were performed on a small animal nano-SPECT/CT imaging system and a small animal nano-PET/MR imaging system (Mediso nano-ScanPM, Mediso Medical Imaging Systems, Budapest, Hungary) individually. Groups of two mice were injected with 3.7 MBq (270 μg) 177Lu-CHX-A″ DTPA-labelled antibody (huA33 wild type, hu3S193 wild type or hu3S193 I253A/H310) and serially imaged at 2 days post injection. Imaging procedures involved anaesthesia of mice by isoflurane. Each mouse was scanned in supine position with its head secured via ear and tooth bars. Respiration was monitored by a pressure-sensitive pad adhered to the abdomen. The imaging study started with a whole body T1-weighted MR scan, followed by a 60-min SPECT scan which was reconstructed into a volumetric image with the voxel size of 0.3 mm × 0.3 mm × 0.3 mm using the Mediso Tera-TOMO® Monte Carlo-based algorithm. Subsequently, reconstructed SPECT and MR images were transferred to a research PACS system where the images could be retrieved for further processing and analysis.
To confirm data obtained from imaging, groups of five mice bearing A431 tumours were injected with 6.29 MBq (100 μg) 177Lu-CHX-A″ DTPA-labelled antibody (huA33 wild type, hu3S193 wild type or hu3S193 I253A/H310) and sacrificed at 48 h post injection. Organs and blood were collected as described before, and the radiolabelled antibody distribution over time was calculated as the mean %ID/g ± SD for each antibody per time point.
To compare tumour uptake at different time points for the mutants versus hu3S193 wild type, two-way ANOVA with the Bonferroni post test was performed using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego California USA www.graphpad.com. Tumour-to-tissue ratios or tissue uptake at specific time points were analysed using one-way ANOVA with Tukey’s multiple comparison post test. When less than three groups were compared, a non-parametric t test (one-tailed) was used.
Production of hu3S193 variants with short elimination half-lives
To investigate whether hu3S193 antibodies with reduced serum persistence would benefit payload delivery, three hu3S193 single variants (I253A, H310A, H435A) and one double variant (I253A/H310A) were generated. All antibodies were expressed in transiently transfected freestyle 293-F cells. Expression yields of antibodies ranged from 15 to 40 mg/L in shake flasks containing 60 mL medium. HiTrap KappaSelect columns were used to purify antibodies. Quality control using SDS-PAGE and HPLC on a Superdex 200 column showed highly pure antibody preparations with >98 % purity. All mutants maintained effective antigen binding in FACS analysis and BIAcore (Additional file 1: Table S1).
Radiolabelling of hu3S193 constructs and huA33 control
Immunoreactive fraction (% total binding) of hu3S193 antibodies incubated in human serum at 37 °C for 6 days
78.64 ± 1.59a
59.09 ± 5.54
32.36 ± 0.12
66.76 ± 0.33
47.50 ± 2.69
30.99 ± 0.77
70.75 ± 3.99
53.52 ± 3.53
32.95 ± 0.28
69.50 ± 0.33
54.59 ± 4.68
34.82 ± 2.98
71.93 ± 3.22
58.29 ± 0.33
30.52 ± 1.45
86.84 ± 0.74
64.46 ± 8.04
40.21 ± 0.62
83.47 ± 4.26
59.16 ± 3.05
40.77 ± 0.53
81.03 ± 3.38
55.83 ± 1.78
35.64 ± 0.29
83.38 ± 3.81
59.70 ± 7.27
46.19 ± 4.63
86.07 ± 2.74
57.18 ± 11.61
42.54 ± 1.15
Blood clearance parameters for 125I- and 111In-CHX-A″ DTPA-labelled hu3S193 antibodies
t 1/2α (h)
Aα a (%ID/g)
t 1/2β (h)
AUCb (%ID/g h)
Biodistribution studies in tumour-bearing mice with 131I- and 111In-CHX-A″ DTPA-labelled hu3S193 antibodies
Tumour uptake, blood levels and tumour-to-blood ratios for 131I- and 111In-CHX-A″ DTPA-labelled hu3S193 antibody variants in A431 tumour-bearing mice
9.02 ± 0.73a
39.37 ± 3.33
13.17 ± 2.40
35.56 ± 5.48
17.37 ± 1.25
22.17 ± 1.81
33.42 ± 7.75
21.83 ± 3.32
17.58 ± 2.60
15.09 ± 1.70
39.01 ± 3.92
14.50 ± 1.11
17.76 ± 1.72
13.18 ± 1.91
39.27 ± 4.33
9.97 ± 1.85
15.10 ± 3.89
7.13 ± 1.46
37.26 ± 8.67
5.78 ± 2.12
11.40 ± 4.56
4.44 ± 1.56
24.24 ± 2.57
1.06 ± 0.32
10.01 ± 3.25
29.95 ± 3.59
9.64 ± 0.74
38.74 ± 3.57
9.95 ± 2.26
6.94 ± 1.34
27.17 ± 2.00
17.99 ± 1.57
5.07 ± 2.10
1.09 ± 0.32
31.75 ± 3.98
10.19 ± 1.04
2.03 ± 0.81
0.04 ± 0.08
33.11 ± 4.05
7.64 ± 1.32
0.78 ± 0.79
0.00 ± 0.00
23.68 ± 6.52
2.99 ± 0.73
0.10 ± 0.14
0.00 ± 0.00
14.66 ± 4.80
1.14 ± 0.63
8.79 ± 0.45
32.46 ± 2.63
10.25 ± 1.30
37.97 ± 2.68
11.52 ± 1.38
8.46 ± 1.89
33.69 ± 3.77
17.09 ± 1.59
5.53 ± 1.18
2.27 ± 1.21
31.10 ± 4.76
7.65 ± 1.60
3.18 ± 0.22
0.69 ± 0.17
28.48 ± 4.00
5.18 ± 1.40
1.64 ± 1.09
0.00 ± 0.00
25.60 ± 4.16
3.19 ± 0.62
0.54 ± 0.58
0.00 ± 0.00
15.34 ± 4.65
1.16 ± 0.62
9.80 ± 1.83
32.56 ± 3.00
10.79 ± 2.87
30.52 ± 5.06
9.58 ± 1.73
3.85 ± 0.35
22.85 ± 2.93
11.05 ± 1.62
5.10 ± 1.87
0.01 ± 0.02
25.10 ± 2.91
5.61 ± 2.01
2.43 ± 1.10
0.00 ± 0.00
22.12 ± 2.55
2.56 ± 0.60
1.81 ± 0.71
0.00 ± 0.00
12.89 ± 1.33
0.54 ± 0.16
1.45 ± 0.99
0.00 ± 0.00
8.64 ± 0.96
0.17 ± 0.06
9.90 ± 2.42
30.20 ± 3.97
8.92 ± 2.00
28.84 ± 6.05
8.04 ± 1.82
3.88 ± 1.32
23.72 ± 0.85
5.28 ± 0.81
5.10 ± 0.76
0.06 ± 0.09
14.84 ± 1.43
0.46 ± 0.07
3.04 ± 1.58
0.00 ± 0.00
11.92 ± 2.46
0.08 ± 0.03
1.92 ± 0.53
0.00 ± 0.00
5.85 ± 1.31
0.00 ± 0.00
1.43 ± 0.27
0.00 ± 0.00
3.52 ± 1.00
0.00 ± 0.00
As expected for large proteins (>60 kDa), all hu3S193 variants exhibited a hepatic clearance. This is evidenced by the 111In-labelled variants showing an increase in liver uptake at early time points with increased blood clearance rates (Fig. 1f). Liver uptake for the slowest clearing mutants hu3S193 H435A and hu3S193 I253A peaked at 4 h p.i. (9.49 ± 0.76 %ID/g and 15.52 ± 3.45 %ID/g, respectively). The fastest mutant hu3S193 I253A/H310A reached a maximum liver uptake at 24 h p.i. (18.68 ± 1.34 %ID/g).
Improved therapeutic ratio with Fc-engineered hu3S193 mutants
AUC values (%ID/g h) and therapeutic ratios of 131I-, 90Y-CHX-A″ DTPA- and 177Lu-CHX-A″ DTPA-labelled hu3S193 antibody variants in A431 tumour-bearing mice
AUC ratios were also calculated for tumour-to-liver and tumour-to-kidney as these clearing organs could be dose limiting, especially for radiometal-labelled mutants. The lowest tumour-to-liver AUC ratios were observed with the 90Y-labelled (1) and 177Lu-labelled (1.9) hu3S193 I253A/H310A. Tumour-to-kidney ratios were lowest for 90Y-hu3S193 I253A (2.4) and 90Y-hu3S193 I253A/H310A (2.5) followed by 90Y-hu3S193 H310A (3.1) and 177Lu-hu3S193 H310A (3.1). Tumour-to-liver AUC ratios were superior for the 131I-labelled variants with the highest tumour-to-liver AUC ratio observed with 131I-hu3S193 I253A/H310A (5.6).
Dosimetry calculation for radioimmunotherapy
Nano-SPECT imaging with 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type and 177Lu-CHX-A″ DTPA-labelled hu3S193 I253A/H310A
Qualitative imaging was performed with hu3S193 wild type, hu3S193 I253A/H310A and huA33 control in A431 tumour-bearing mice. Mice were injected with 3.7 MBq (100 μCi, 270 μg) of radiolabelled antibody. HuA33 wild type was used as a negative control as the A431 cell line does not express A33 antigen. Quality controls showed that at day 0, only 3.4 % of 177Lu-CHX-A″ DTPA-labelled huA33 bound to A431 cells in vitro. In contrast, 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type and I253A/H310A demonstrated a good binding at day 0 (72.6 ± 4.3 % and 53.9 ± 3.9 %, respectively; n = 3, SD) gradually decreasing to 25.0 ± 2.5 % (wild type) versus 18.4 ± 1.4 % (I253A/H310A) after 6 days of incubation in human serum at 37 °C.
Biodistribution at 48 h post injection of 177Lu-CHX-A″ DTPA-labelled hu3S193 wild type and I253A/H310A in tumour-bearing mice
Hu3S193 wild type
44.81 ± 3.35
16.95 ± 3.60
10.35 ± 0.54
15.67 ± 2.47
1.05 ± 0.27
20.88 ± 1.25
5.99 ± 1.43
14.16 ± 1.28
6.37 ± 0.62
9.32 ± 1.33
13.77 ± 2.57
9.60 ± 0.88
8.27 ± 4.36
3.91 ± 0.41
7.98 ± 0.51
9.79 ± 1.55
1.95 ± 0.25
12.06 ± 0.99
5.72 ± 1.09
2.66 ± 0.16
6.03 ± 0.49
2.01 ± 0.44
1.03 ± 0.08
2.34 ± 0.44
Higher protein doses were used for imaging with 177Lu-CHX-A″ DTPA-labelled hu3S193 antibodies (270 μg) and biodistribution (100 μg). Tumour uptake with 5 μg (~0.25 mg/kg) 111In-CHX-A″ DTPA-labelled hu3S193 antibodies was not significantly different from tumour uptake with 100 μg (~5 mg/kg) 177Lu-CHX-A″ DTPA-labelled hu3S193 antibodies as shown in Additional file 1: Figure S3, suggesting that at least at the 5 mg/kg dose level, no blocking of receptor has occurred.
Fc engineering is a promising technique to increase the therapeutic ratio for payload delivery. This approach aims to increase the therapeutic efficacy by reducing the terminal half-life of antibodies or Fc-containing antibody constructs, thus reducing the dose-limiting toxicity to the blood and bone marrow of intact radiolabelled therapeutic antibodies. In this study, four variants of an intact IgG1 antibody, hu3S193, with a broad range in half-life were created by site-directed mutagenesis and analysed in blood clearance studies and biodistribution studies. Our results show that hu3S193 can be engineered with improved therapeutic ratios for 90Y- and 177Lu-based therapy, with the best candidate being hu3S193 I253A/H310A for 177Lu-based therapy, achieving almost double tumour-to-blood AUC ratios compared to wild-type hu3S193.
Four Fc variants of an intact IgG1 antibody, hu3S193, with a broad range in serum half-life were created by site-directed mutagenesis and analysed in preclinical blood clearance studies and biodistribution studies. Non-specific uptake of hu3S193 wild type in a Lewis-Y-negative cell line SW1222 is known to be low ; in addition, in this study, a non-specific IgG1 control antibody huA33 showed low uptake in A431 tumours at 72 h post injection. Therefore, the tumour uptake of radiolabelled hu3S193 mutants was specific and antigen-mediated.
Early engineering approaches using deletion of constant domains to reduce the serum half-life of antibodies have shown that tumour-to-normal dose ratios can be improved [1, 10, 11, 37]. More recently, studies by Kenanova et al. reported on therapy prospects of radioiodinated and radiometal-labelled Fc-engineered anti-carcinoembryonic antigen (CEA) scFv-Fc fragments [20, 21]. Dosimetry calculations predicted that the 131I-labelled scFv-Fc H310A/H435Q could deliver >7000 cGy, limited by red marrow toxicity. 90Y-labelled scFv-Fc I253A was best suited for 90Y delivery, although dose predictions did not match the intact cT84.66 antibody. The current study extends their findings to an intact IgG1 and includes predictions for 177Lu-based therapy. In contrast to the anti-CEA study by Kenanova et al., the radioiodinated anti-Ley hu3S193 variants cleared much faster than the radioiodinated scFv-Fc fragments, and therefore, no therapeutic benefit could be obtained from the radioiodinated hu3S193 variants. The hu3S193 variants might be more sensitive to deiodination in vivo compared to the scFv-Fc variants. To study the benefit for RIT of using radioiodinated hu3S193 variants with faster blood clearance, other radioiodination methods such as site-specific radioiodination of cysteine-containing hu3S193 variants could be explored .
Whilst a doubling in dose to the maximum predicted dose calculated for hu3S193 wild type was predicted and a doubling in the tumour-to-blood AUC ratios achieved, the dose needed for tumour eradication in patients is likely to be higher than that achievable with a single infusion. Ley-expressing tumours such as colon, lung, ovarian and breast cancer require radiation doses of at least 60 Gy to eradicate solid tumours in patients . Reducing the half-life of systemically administered antibodies is usually associated with reduced uptake in tumour; however, AUC ratios of tumour and blood address the varying effects of alterations in antibody kinetics, and our results confirm that selective IgG1 mutations do provide benefit in therapeutic ratios. Approaches to further increase therapeutic efficacy of Fc-engineered intact antibodies with reduced half-lives can include dose fractionation , use in pretargeting radioimmunotherapy approaches  or combination with chemotherapy [28, 29]. To date, pretargeting approaches show advantages compared to improvements in one-step RIT for improved tumour-to-normal tissue AUC ratios and tumour responses in preclinical models of solid tumours , but challenges remain to develop non-immunogenic and translatable approaches for human trials.
Due to the toxicity limitations of RIT and patient tumour variability, it is useful to develop theranostics to guide dosimetry in patients, exemplified in this study by 177Lu-labelled I253A/H310A. The imaging results reflect the biodistribution data; the highest tumour uptake was seen with hu3S193 wild type, but specific tumour uptake was still achievable with the fastest clearing hu3S193 variant I253A/H310A, and tumour-to-blood ratios were far higher at earlier time points with the mutant hu3S193 constructs. However, because 177Lu can only be imaged using SPECT cameras, a PET equivalent such as 89Zr-labelled I253A/H310A might be a better alternative and may allow better quantification of tumour uptake and saturability in vivo. We are currently evaluating 89Zr-labelled hu3S193 variants in tumour-bearing mice in small animal PET studies.
A higher protein dose was used for 177Lu-imaging (270 μg) and biodistribution (100 μg) studies versus 111In-biodistribution (5 μg) studies. We demonstrated that tumour uptake at 5 and 100 μg protein doses were comparable. Lewis-Y expression is very high on A431 cells and similar to MCF-7 cells, estimated to express around 106–107 antibody binding sites . A recent report on ABT-806, a humanised antibody that specifically targets epidermal growth factor receptor (EGFR), reports on cold competition blocking of the 806 antibody in A431 tumours . EGFR is highly expressed in A431 cells, and therefore, more than 20 mg/kg of cold ABT-806 antibody was needed to allow competition in vivo. It is therefore expected that competition with hu3S193 antibodies will only occur at doses higher than 20 mg/kg, which aligns with the observation that at the 5 mg/kg dose (100 μg), no reduction in tumour uptake was observed at 48 h post injection.
Although significant increases in therapeutic doses were predicted with some variants compared to hu3S193 wild type, increased toxicities to normal tissue such as the liver and kidneys were also predicted. A shift in toxicity from the bone marrow to liver as toxicity limiting organ for radiometal-labelled antibody variants with a faster blood clearance is not surprising. As the antibody variants clear faster from the body, radioactivity exposure to the blood is reduced. In addition, due to the reduced binding affinity of the variants for FcRn, an increase in catabolism is expected as the variants are no longer recycled in the blood circulation and degraded in the lysosomes (e.g. hu3S193 I253A/H310A) . In contrast to radioiodine, the small radiometal-labelled metabolites are trapped in the lysosomes of hepatocytes , and thus, a higher initial uptake of radioactivity observed in the liver is the result of enhanced accumulation of radiometal chelates after degradation of the variants in the lysosomes of hepatocytes. However, a mouse model might not be readily translatable to human studies to estimate liver and kidney toxicities developing from catabolites due to differences in stability of radiolabelled conjugates in human serum and relative size of tissue compartments between mouse and human. A theranostic might therefore also aid in appropriate dose selection when using engineered intact antibodies with altered pharmacokinetics.
Four Fc variants of an intact IgG1 antibody, hu3S193, with a broad range in serum half-life were created by site-directed mutagenesis and analysed in preclinical blood clearance studies and biodistribution studies. We have shown that hu3S193 can be engineered with improved therapeutic ratios for 90Y- and 177Lu-based therapy, with the best candidate being hu3S193 I253A/H310A for 177Lu-based therapy. These results are highly relevant to utilising Fc engineering as a tool to improve the clinical application of hu3S193 and other intact antibodies especially for payload delivery.
Compliance with ethical standards
This research was supported by National Health and Medical Research Council Project Grants 542512, 1030469, National Health and Medical Research Council Program grant 487922, National Health and Medical Research Council Practitioner Fellowship (A.M.S.), and in part by Ludwig Cancer Research, by funds from the Operational Infrastructure Support Program provided by the Victorian Government, and the Intramural Research Program of the NIH, National Cancer Institute, Centre for Cancer Research.
Research involving Human Participants and/or Animals
Statement of human rights
This article does not contain any studies with human participants by any of the authors.
Statement on the welfare of animals
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347–60. doi:10.1038/nrc3925.View ArticlePubMedGoogle Scholar
- Brambell FW. The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet. 1966;2:1087–93.View ArticlePubMedGoogle Scholar
- Roopenian DC, Christianson GJ, Sproule TJ, Brown AC, Akilesh S, Jung N, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170:3528–33.View ArticlePubMedGoogle Scholar
- Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93:5512–6.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol. 1996;26:690–6. doi:10.1002/eji.1830260327.View ArticlePubMedGoogle Scholar
- Simister NE, Mostov KE. An Fc receptor structurally related to MHC class I antigens. Nature. 1989;337:184–7. doi:10.1038/337184a0.View ArticlePubMedGoogle Scholar
- Stein R, Govindan SV, Chen S, Reed L, Richel H, Griffiths GL, et al. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I. J Nucl Med. 2001;42:967–74.PubMedGoogle Scholar
- Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123–9.PubMedGoogle Scholar
- Naruki Y, Carrasquillo JA, Reynolds JC, Maloney PJ, Frincke JM, Neumann RD, et al. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad Appl Instrum B. 1990;17:201–7.View ArticlePubMedGoogle Scholar
- Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126–36. doi:10.1038/nbt1142.View ArticlePubMedGoogle Scholar
- Burvenich IJG, Scott AM. The delivery construct: maximizing the therapeutic ratio of targeted radionuclide therapy. In: Speer TW, editor. Targeted radionuclide therapy. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 236–48.Google Scholar
- Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res. 2000;60:4804–11.PubMedGoogle Scholar
- Tahtis K, Lee FT, Smyth FE, Power BE, Renner C, Brechbiel MW, et al. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model. Clin Cancer Res. 2001;7:1061–72.PubMedGoogle Scholar
- Kelly MP, Lee FT, Tahtis K, Power BE, Smyth FE, Brechbiel MW, et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother Radiopharm. 2008;23:411–23. doi:10.1089/cbr.2007.0450.View ArticlePubMedPubMed CentralGoogle Scholar
- Goodwin DA, Meares CF, Osen M. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system. J Nucl Med. 1998;39:1813–8.PubMedGoogle Scholar
- Kim JK, Firan M, Radu CG, Kim CH, Ghetie V, Ward ES. Mapping the site on human IgG for binding of the MHC class I-related receptor. FcRn Eur J Immunol. 1999;29:2819–25. doi:10.1002/(SICI)1521-4141(199909)29:09<2819::AID-IMMU2819>3.0.CO;2-6.View ArticlePubMedGoogle Scholar
- Martin WL, West Jr AP, Gan L, Bjorkman PJ. Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding. Mol Cell. 2001;7:867–77. doi:10.1016/S1097-2765(01)00230-1.View ArticlePubMedGoogle Scholar
- Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276:6591–604. doi:10.1074/jbc.M009483200.View ArticlePubMedGoogle Scholar
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25. doi:10.1038/nri2155.View ArticlePubMedGoogle Scholar
- Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65:622–31.PubMedPubMed CentralGoogle Scholar
- Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. Cancer Res. 2007;67:718–26. doi:10.1158/0008-5472.CAN-06-0454.View ArticlePubMedGoogle Scholar
- Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, et al. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009;50:1500–8. doi:10.2967/jnumed.108.060426.View ArticlePubMedPubMed CentralGoogle Scholar
- Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in pancreas cancer xenografts with a mutated scFv-Fc antibody fragment. EJNMMI Res. 2011;1:24. doi:10.1186/2191-219X-1-24.View ArticlePubMedPubMed CentralGoogle Scholar
- Hornick JL, Sharifi J, Khawli LA, Hu P, Bai WG, Alauddin MM, et al. Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors. J Nucl Med. 2000;41:355–62.PubMedGoogle Scholar
- Burvenich IJG, Farrugia W, Lee FT, Catimel B, Liu Z, Makris D, et al. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor. MAbs, in press Google Scholar
- Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res. 2000;6:3621–8.PubMedGoogle Scholar
- Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, et al. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478. Clin Cancer Res. 2005;11:7080s–6s. doi:10.1158/1078-0432.CCR-1004-0019.View ArticlePubMedGoogle Scholar
- Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med. 2006;47:716–25.PubMedGoogle Scholar
- Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, et al. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate. 2009;69:92–104. doi:10.1002/pros.20856.View ArticlePubMedPubMed CentralGoogle Scholar
- Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, et al. A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res. 2007;13:3286–92.View ArticlePubMedGoogle Scholar
- Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res. 2000;60:3254–61.PubMedGoogle Scholar
- Scott AM, Lee FT, Jones R, Hopkins W, MacGregor D, Cebon JS, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res. 2005;11:4810–7. doi:10.1158/1078-0432.CCR-04-2329.View ArticlePubMedGoogle Scholar
- Lee FT, O'Keefe GJ, Gan HK, Mountain AJ, Jones GR, Saunder TH, et al. Immuno-PET quantitation of de2-7 epidermal growth factor receptor expression in glioma using 124I-IMP-R4-labeled antibody ch806. J Nucl Med. 2010;51:967–72. doi:10.2967/jnumed.109.068395.View ArticlePubMedGoogle Scholar
- Nikula TK, Curcio MJ, Brechbiel MW, Gansow OA, Finn RD, Scheinberg DA. A rapid, single vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol. 1995;22:387–90.View ArticlePubMedGoogle Scholar
- Wu C, Kobayashi H, Sun B, Yoo TM, Paik CH, Gansow OA, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem. 1997;5:1925–34.View ArticlePubMedGoogle Scholar
- Lee FT, Rigopoulos A, Hall C, Clarke K, Cody SH, Smyth FE, et al. Specific localization, gamma camera imaging, and intracellular trafficking of radiolabelled chimeric anti-G(D3) ganglioside monoclonal antibody KM871 in SK-MEL-28 melanoma xenografts. Cancer Res. 2001;61:4474–82.PubMedGoogle Scholar
- Shen S, Forero A, Meredith RF, LoBuglio AF. Biodistribution and dosimetry of In-111/Y-90-HuCC49ΔCh2 (IDEC-159) in patients with metastatic colorectal adenocarcinoma. Cancer Biother Radiopharm. 2011;26:127–33. doi:10.1089/cbr.2010.0864.View ArticlePubMedGoogle Scholar
- Strand J, Nordeman P, Honarvar H, Altai M, Orlova A, Larhed M, et al. Site-specific radioiodination of HER2-targeting affibody molecules using 4-iodophenethylmaleimide decreases renal uptake of radioactivity. ChemistryOpen. 2015;4:174–82. doi:10.1002/open.201402097.View ArticlePubMedPubMed CentralGoogle Scholar
- Ocean AJ, Pennington KL, Guarino MJ, Sheikh A, Bekaii-Saab T, Serafini AN, et al. Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial. Cancer. 2012;118:5497–506. doi:10.1002/cncr.27592.View ArticlePubMedPubMed CentralGoogle Scholar
- Cheal SM, Xu H, Guo HF, Zanzonico PB, Larson SM, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014;13:1803–12. doi:10.1158/1535-7163.MCT-13-0933.View ArticlePubMedPubMed CentralGoogle Scholar
- Reilly EB, Phillips AC, Buchanan FG, Kingsbury G, Zhang Y, Meulbroek JA, et al. Characterization of ABT-806, a humanized tumor-specific anti-EGFR monoclonal antibody. Mol Cancer Ther. 2015;14:1141–51. doi:10.1158/1535-7163.MCT-14-0820.View ArticlePubMedGoogle Scholar
- Duncan JR, Behr TM, DeNardo SJ. Intracellular fate of radiometals. J Nucl Med. 1997;38:829.PubMedGoogle Scholar